Untangling the Controversy: Impact and Management of Iron Overload in MDS

November 3, 2011 - New York, New York

New York Marriott at the Brooklyn Bridge Salon E-I

Chair: Alan F. List, MD
H. Lee Moffit Cancer Center and Research Institute
Tampa, Florida

A Luncheon Symposium at the 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Scientific Agenda:

11:15 am Lunch
11:35 am Welcome and pre-activity ARS
   Alan F. List, MD
11:40 am Putting the iron overload management guidelines into practice – patient selection, drug selection, and monitoring
   Jerry L. Spivak, MD, FACP
12:00 pm Debate: Should iron overload be a focus of treatment in MDS patients?
   Yes, the benefits of iron chelation outweigh the costs
   Heather Leitch, MD, PhD, FRCP
   No, MDS treatment should focus on reducing transfusion dependence and other goals
   David P. Steensma, MD
12:30 pm Future management of iron overload in MDS – recent findings and ongoing trials
   Alan F. List, MD
12:50 pm Panel discussion and Q&A
1:00 pm Concluding remarks and post-activity ARS
   Alan F. List, MD
1:05 pm Adjourn

Faculty:

Heather Leitch, MD, PhD, FRCP
Providence Hematology
Vancouver, Canada

Alan F. List, MD
H. Lee Moffit Cancer Center & Research Institute
Tampa, Florida

Jerry L. Spivak, MD, FACP
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

David P. Steensma, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts